Oncolytic virus improved in safety and anticancer effect
AssigneeBionoxx Inc.
InventorsTaeho HWANG, Mong CHO
Life of this patent
Estimating the term…
Abstract
A recombinant oncolytic virus with improved safety and anticancer effect and a use thereof are disclosed. The recombinant oncolytic virus is obtained by inserting an HSV-TK fragment-encoding gene into a TK gene region to delete TK of Vaccinia virus. The oncolytic virus expresses an HSV-TK fragment to phosphorylate GCV so that cancer cells infected with the oncolytic virus and their neighboring cancer cells can be killed. GCV is also involved in the suppression of viral proliferation and thus can control side effects caused by a virus even upon the administration of a high dose of the virus.
Claims46
A recombinant virus vector comprising an exogenous nucleotide sequence encoding an HSV-TK (herpes simplex virus thymidine kinase) fragment or a variant thereof.
(canceled)
(canceled)
(canceled)
A method for preparing a recombinant vaccinia virus which expresses an HSV-TK fragment or a variant thereof, comprising the steps of:
- i) transfecting a shuttle plasmid comprising a nucleotide sequence encoding an HSV-TK fragment or a variant thereof into a host cell, and treating the host cell with a wild type vaccinia virus;
- ii) culturing the resulting host cell;
- and
- iii) obtaining the recombinant vaccinia virus from the resulting culture.
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.